Linked Life Data

12573019

Source:http://linkedlifedata.com/resource/pubmed/id/12573019

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-2-7
pubmed:abstractText
Hybridoma cultures are routinely used as a source for monoclonal antibody (mAb) production necessary for preclinical evaluation. However, these cultures typically have low volumetric and specific productivities. In this article, we examined the use and the timing of addition of dimethyl sulfoxide (DMSO) as a medium additive to improve mAb production in our hybridoma clone 19 (c19) cultures. From shake flask studies, we defined the optimal DMSO concentration and time of addition for improved productivity. This timing coordinated with high cell viability and density. Hybridoma cultures treated with DMSO up to 0.3% (v/v) possessed cell densities and viabilities comparable to untreated control. We demonstrated that 0.2% (v/v) DMSO added to shake flask cultures at their maximal viable cell densities resulted in a 2-fold increase in specific mAb production. This procedure was scaleable up to 20 L Cellbags (Wave Bioreactors) with similar titer improvement. Moreover, DMSO treatment did not affect the bioactivity or glycosylation profiles of the mAb.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
8756-7938
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
158-62
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Improvement of monoclonal antibody production in hybridoma cells by dimethyl sulfoxide.
pubmed:affiliation
Biotechnology Development, Tumor Biology, Schering-Plough Research Institute, 1011 Morris Avenue, Union, New Jersey 07083, USA. wai_lam.ling@spcorp.com
pubmed:publicationType
Journal Article, Comparative Study, Evaluation Studies